Search Results
Your search for Mansoor Raza Mirza, MD matches 18 pages
Showing 1 - 18Dostarlimab-Based Combinations in Advanced Endometrial Cancer
Statistically significant and clinically meaningful overall survival results from Part 1 and progression-free survival results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial in adult patients with primary advanced or recurrent endometrial cancer were presented in a late-breaking...
RUBY Trial: Dostarlimab Plus Carboplatin and Paclitaxel in Advanced Endometrial Cancer
Adding immunotherapy to standard chemotherapy for the first-line treatment of advanced or the first recurrence of endometrial cancer significantly improved progression-free survival compared to chemotherapy alone, according to data presented by Mansoor Raza Mirza, MD, and colleagues at the March...
Phase III NORA Trial: Niraparib Maintenance Shows Overall Survival Trend in Platinum-Sensitive Recurrent Ovarian Cancer
Maintenance therapy with a poly (ADP-ribose) polymerase (PARP) inhibitor may do more than just delay disease progression for patients with platinum-sensitive, relapsed ovarian cancer; it might also improve overall survival, according to data presented during the December 2022 European Society for...
Phase III NORA Study: Niraparib Maintenance Shows Favorable Overall Survival Trend in Platinum-Sensitive Recurrent Ovarian Cancer
Poly (ADP-ribose) polymerase (PARP) inhibitor maintenance therapy may do more than just delay disease progression for patients with platinum-sensitive, relapsed ovarian cancer; it might also improve overall survival, according to data presented by Mansoor Raza Mirza, MD, during the December Virtual ...
Expert Point of View: Mansoor Raza Mirza, MD
“The standard of care [in advanced cervical cancer] has been the addition of bevacizumab to platinum-based chemotherapy since 2014. Even with the addition of bevacizumab, we still need to do better. There is a substantial unmet need for new therapies,” said invited discussant Mansoor Raza Mirza,...
KEYNOTE-826: Pembrolizumab Plus Chemotherapy in Advanced Cervical Cancer
The addition of pembrolizumab to chemotherapy prolonged survival in recurrent, persistent, or metastatic cervical cancer, according to results of the KEYNOTE-826 study presented at the European Society for Medical Oncology (ESMO) Congress 2021 by Nicoletta Colombo, MD, and colleagues (Abstract...
Expert Point of View: Mansoor Raza Mirza, MD
The invited discussant of EMPOWER-Cervical 1 was Mansoor Raza Mirza, MD, Chief Oncologist at Copenhagen University Hospital and Chairman of the European Network of Gynaecological Oncology Trials group (ENGOT). Dr. Mirza called the findings “amazing” and predicted they will “usher in a new era” in...
Immunotherapy With Cemiplimab-rwlc Yields Survival Benefit in Advanced Cervical Cancer
The PD-L1 inhibitor cemiplimab-rwlc has become the first immunotherapy to yield a statistically significant and clinically meaningful survival benefit in recurrent or metastatic cervical cancer progressing after first-line platinum-containing chemotherapy. Patients were enrolled irrespective of...
Expert Point of View: Mansoor Raza Mirza, MD
The invited discussant of EMPOWER-Cervical 1 was Mansoor Raza Mirza, MD, Chief Oncologist at Copenhagen University Hospital and Chairman of the European Network of Gynaecological Oncology Trials group (ENGOT). Dr. Mirza called the findings “amazing” and predicted they will “usher in a new era” in...
Immunotherapy With Cemiplimab-rwlc Yields Survival Benefit in Advanced Cervical Cancer
The PD-L1 inhibitor cemiplimab-rwlc has become the first immunotherapy to yield a statistically significant and clinically meaningful survival benefit in recurrent or metastatic cervical cancer progressing after first-line platinum-containing chemotherapy. Patients were enrolled irrespective of...
Mansoor Raza Mirza, MD, on Endometrial Cancer: Palbociclib Plus Letrozole in ER-Positive Disease
Mansoor Raza Mirza, MD, of Copenhagen University Hospital, discusses phase II study results that showed the combination of palbociclib and letrozole, compared with placebo plus letrozole, improved progression-free survival in patients with estrogen receptor–positive advanced or recurrent...
Final Analysis of Phase II Trial in Recurrent Platinum-Sensitive Ovarian Cancer
In a poster presentation at the ASCO20 Virtual Scientific Program, Mansoor Raza Mirza, MD, of the the Department of Oncology, Rigshopitalet, Copenhagen University Hospital, Denmark, and colleagues reported the final analysis of the phase II NSGO-AVANOVA2/ENGOT-OV24 trial comparing the...
Three Phase III Trials Suggest Paradigm Shift With PARP Inhibitors in Ovarian Cancer
Ovarian cancer is typically a second-tier newsmaker at the world’s premier oncology conferences, but at the European Society for Medical Oncology (ESMO) Congress 2019, this tumor type generated universal buzz. Impressive findings were presented for three PARP inhibitors in front-line maintenance...
Bevacizumab/Niraparib vs Niraparib Alone for Platinum-Sensitive Recurrent Ovarian Cancer
In the phase II NSGO-AVANOVA2/ENGOT-ov24 trial reported in The Lancet Oncology, Mansoor Raza Mirza, MD, and colleagues found that the combination of bevacizumab plus niraparib prolonged progression-free survival vs niraparib alone in women with platinum-sensitive recurrent ovarian cancer. Study...
Mansoor Raza Mirza, MD, and Don S. Dizon, MD, on Recurrent Platinum-Sensitive Ovarian Cancer: Niraparib Plus Bevacizumab
Don S. Dizon, MD, of the Lifespan Cancer Institute, and Mansoor Raza Mirza, MD, of Copenhagen University Hospital, discuss study findings that showed, compared with niraparib alone, niraparib plus bevacizumab improved progression-free survival in women with recurrent platinum-sensitive ovarian...
Olaparib Maintenance in Ovarian Cancer: Outcomes Reconsidered
An article that appeared in the April 10 issue of The ASCO Post (“Olaparib Maintenance Prolongs Progression-Free Survival in Ovarian Cancer”) suggests unwarranted conclusions from the phase III SOLO2 trial of olaparib (Lynparza) in patients with platinum-sensitive relapsed ovarian cancer and...
ESMO 2016: Niraparib Significantly Improves Outcomes in Platinum-Sensitive Recurrent Ovarian Cancer
The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented by Mirza et al at the 2016 European Society for Medical Oncology (ESMO) Congress in Copenhagen (Abstract LBA3_PR), and...
Mansoor Raza Mirza, MD, on Ovarian Cancer: Results From the ENGOT-OV16/NOVA Trial
Mansoor Raza Mirza, MD, of Rigshospitalet, Copenhagen University Hospital, discusses phase III study findings on maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer. (Abstract LBA3)
